$719 Million is the total value of Octagon Capital Advisors LP's 41 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 52.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| APLS | Sell | APELLIS PHARMACEUTICALS INC | $238,527,130 | +11.3% | 2,618,300 | -19.4% | 33.19% | +7.6% |
| VRNA | VERONA PHARMA PLCsponsored ads | $52,173,520 | +5.3% | 2,468,000 | 0.0% | 7.26% | +1.8% | |
| CBAY | CYMABAY THERAPEUTICS INC | $50,051,552 | +25.6% | 4,570,918 | 0.0% | 6.96% | +21.4% | |
| RCUS | Sell | ARCUS BIOSCIENCES INC | $39,970,080 | +0.9% | 1,968,000 | -9.4% | 5.56% | -2.4% |
| ROIVANT SCIENCES LTD | $39,352,320 | +36.6% | 3,904,000 | 0.0% | 5.48% | +32.1% | ||
| MRTX | MIRATI THERAPEUTICS INC | $27,097,500 | -2.8% | 750,000 | 0.0% | 3.77% | -6.0% | |
| CLDX | CELLDEX THERAPEUTICS INC NEW | $25,783,339 | -5.7% | 759,898 | 0.0% | 3.59% | -8.8% | |
| VRDN | Sell | VIRIDIAN THERAPEUTICS INC | $21,958,170 | -27.2% | 923,000 | -22.1% | 3.06% | -29.6% |
| BBIO | Sell | BRIDGEBIO PHARMA INC | $20,970,240 | -5.5% | 1,219,200 | -8.9% | 2.92% | -8.6% |
| ETNB | Buy | 89BIO INC | $20,215,557 | +231.8% | 1,066,784 | +166.7% | 2.81% | +220.8% |
| New | DISC MEDICINE INC | $18,426,000 | – | 415,000 | +100.0% | 2.56% | – | |
| VIR | New | VIR BIOTECHNOLOGY INC | $15,946,953 | – | 650,100 | +100.0% | 2.22% | – |
| RPHM | Buy | RENEO PHARMACEUTICALS INC | $15,537,931 | +518.6% | 2,368,587 | +463.9% | 2.16% | +498.9% |
| TNDM | TANDEM DIABETES CARE INC | $11,654,758 | -39.6% | 474,929 | 0.0% | 1.62% | -41.5% | |
| AVTE | AEROVATE THERAPEUTICS INC | $10,662,361 | -15.0% | 621,712 | 0.0% | 1.48% | -17.7% | |
| ITOS | ITEOS THERAPEUTICS INC | $7,891,040 | -2.7% | 596,000 | 0.0% | 1.10% | -5.9% | |
| DYN | DYNE THERAPEUTICS INC | $7,795,631 | -2.3% | 692,945 | 0.0% | 1.08% | -5.6% | |
| INSM | New | INSMED INC | $7,743,700 | – | 367,000 | +100.0% | 1.08% | – |
| ALPN | Sell | ALPINE IMMUNE SCIENCES INC | $7,710,000 | -16.9% | 750,000 | -37.6% | 1.07% | -19.6% |
| TVTX | TRAVERE THERAPEUTICS INC | $7,603,200 | -31.7% | 495,000 | 0.0% | 1.06% | -34.0% | |
| GERN | GERON CORP | $7,312,380 | +47.9% | 2,278,000 | 0.0% | 1.02% | +43.2% | |
| XILIO THERAPEUTICS INC | $6,353,500 | -17.4% | 2,425,000 | 0.0% | 0.88% | -20.1% | ||
| New | AN2 THERAPEUTICS INC | $6,127,650 | – | 720,900 | +100.0% | 0.85% | – | |
| Sell | JASPER THERAPEUTICS INC | $6,121,316 | -47.0% | 4,468,114 | -30.0% | 0.85% | -48.7% | |
| VKTX | VIKING THERAPEUTICS INC | $6,078,750 | -2.6% | 375,000 | 0.0% | 0.85% | -5.8% | |
| ANNX | Buy | ANNEXON INC | $5,843,200 | +27.5% | 1,660,000 | +39.5% | 0.81% | +23.4% |
| GLYC | GLYCOMIMETICS INC | $5,220,000 | +38.1% | 3,000,000 | 0.0% | 0.73% | +33.5% | |
| GOSS | Buy | GOSSAMER BIO INC | $4,749,683 | +92.5% | 3,958,069 | +102.1% | 0.66% | +86.2% |
| LXRX | New | LEXICON PHARMACEUTICALS INC | $4,403,844 | – | 1,923,076 | +100.0% | 0.61% | – |
| Sell | STRUCTURE THERAPEUTICS INCsponsored ads | $3,117,750 | +39.9% | 75,000 | -20.0% | 0.43% | +35.2% | |
| PMVP | New | PMV PHARMACEUTICALS INC | $2,942,200 | – | 470,000 | +100.0% | 0.41% | – |
| CNTA | Buy | CENTESSA PHARMACEUTICALS PLCsponsored ads | $2,549,834 | +67.2% | 411,928 | +4.0% | 0.36% | +62.1% |
| ORIC | New | ORIC PHARMACEUTICALS INC | $2,149,520 | – | 277,000 | +100.0% | 0.30% | – |
| STOK | STOKE THERAPEUTICS INC | $1,973,661 | +27.6% | 185,669 | 0.0% | 0.28% | +23.3% | |
| ISEE | New | IVERIC BIO INCput | $1,967,000 | – | 50,000 | +100.0% | 0.27% | – |
| New | HEPION PHARMACEUTICALS INC | $1,627,500 | – | 155,000 | +100.0% | 0.23% | – | |
| VERA | Sell | VERA THERAPEUTICS INCcl a | $1,123,500 | -81.8% | 70,000 | -91.2% | 0.16% | -82.4% |
| PIRS | Buy | PIERIS PHARMACEUTICALS INC | $1,092,300 | +271.2% | 6,600,000 | +2089.1% | 0.15% | +261.9% |
| MGTA | New | MAGENTA THERAPEUTICS INC | $416,900 | – | 550,000 | +100.0% | 0.06% | – |
| INZY | New | INOZYME PHARMA INC | $276,840 | – | 49,702 | +100.0% | 0.04% | – |
| GLUE | New | MONTE ROSA THERAPEUTICS INC | $136,315 | – | 19,900 | +100.0% | 0.02% | – |
| VECT | Exit | VECTIVBIO HLDG AG | $0 | – | -35,259 | -100.0% | -0.04% | – |
| BBIO | Exit | BRIDGEBIO PHARMA INCcall | $0 | – | -100,000 | -100.0% | -0.24% | – |
| ACRS | Exit | ACLARIS THERAPEUTICS INC | $0 | – | -577,000 | -100.0% | -0.67% | – |
| ITCI | Exit | INTRA-CELLULAR THERAPIES INC | $0 | – | -94,700 | -100.0% | -0.74% | – |
| RNA | Exit | AVIDITY BIOSCIENCES INC | $0 | – | -382,000 | -100.0% | -0.84% | – |
| FDMT | Exit | 4D MOLECULAR THERAPEUTICS IN | $0 | – | -499,996 | -100.0% | -1.24% | – |
| KDNY | Exit | CHINOOK THERAPEUTICS INC | $0 | – | -2,551,703 | -100.0% | -8.50% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APELLIS PHARMACEUTICALS INC | 12 | Q3 2023 | 33.2% |
| ARCUS BIOSCIENCES INC | 12 | Q3 2023 | 18.1% |
| CELLDEX THERAPEUTICS INC NEW | 12 | Q3 2023 | 10.1% |
| GOSSAMER BIO INC | 12 | Q3 2023 | 6.2% |
| 4D MOLECULAR THERAPEUTICS IN | 10 | Q1 2023 | 6.6% |
| BRIDGEBIO PHARMA INC | 10 | Q3 2023 | 6.6% |
| AVIDITY BIOSCIENCES INC | 10 | Q1 2023 | 3.8% |
| VERA THERAPEUTICS INC | 9 | Q2 2023 | 3.5% |
| DYNE THERAPEUTICS INC | 9 | Q3 2023 | 3.5% |
| STOKE THERAPEUTICS INC | 9 | Q2 2023 | 3.7% |
View Octagon Capital Advisors LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-06 |
| SC 13G/A | 2024-02-05 |
| SC 13G | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-25 |
| 13F-HR | 2022-11-14 |
View Octagon Capital Advisors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.